ERBB2 and breast carcinoma: To test the efficacy of a combination of HER2 blockade with mTOR inhibition as a potential therapeutic strategy to overcome resistance to trastuzumab in HER2-positive breast cancer cell line (BCCL) models, we first developed four different cellular models with acquired resistance to trastuzumab [24].